Drug Trial Radar · NCT04491838
Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: Mar 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Aug 3, 2020
Primary completion
Mar 5, 2021
Study completion Mar 5, 2021
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jul 29, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study is to compare the pharmacokinetic(PK) profile of pozelimab produced by the original manufacturing process (Process A) compared to a second manufacturing process (Process B) The secondary objectives of the study are: * Assess the safety and tolerability of a single SC dose of pozelimab produced by the 2 manufacturing processes * Assess the immunogenicity of pozelimab produced by the 2 manufacturing processes
Conditions
- Healthy Volunteer
Interventions
PozelimabDrug
Single subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the time of the last positive concentration (AUClast) pharmacokinetic (PK) profile of pozelimab in Process ATime frame: Up to 16 weeks
- Assess the time of the last positive concentration (AUClast) PK profile of pozelimab in Process BTime frame: Up to 16 weeks
- Assess peak concentration (Cmax) PK profile of pozelimabin in Process ATime frame: Up to 16 weeks
- Assess peak concentration (Cmax) PK profile of pozelimab in Process BTime frame: Up to 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Regeneron Study Site
Antwerp, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.